Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.

To compare the effects of 1) tibolone, 2) continuous combined oestrogen plus progestogen and 3) placebo on plasma lipid and lipoprotein markers of cardiovascular risk in healthy post-menopausal women.randomised, single-centre, placebo-controlled, double-blind study PATIENTS: 101 post-menopausal women were randomised (1:1:1) into one of three groups taking daily 2.5mg tibolone, continuous oral oestradiol-17β 2mg plus norethisterone acetate 1mg daily (E2 /NETA) or placebo.Fasting serum lipid, lipoprotein and apolipoprotein concentrations measured at baseline and after 6, 12 and 24 months of treatment.Both tibolone and E2 /NETA lowered plasma total cholesterol concentrations relative to placebo. With tibolone, high-density lipoprotein cholesterol (HDL-C) was reduced (-27% at 24 months, p<0.001), the greatest effect being in the cholesterol-enriched HDL2 subfraction (-40%, p<0.001). Tibolone’s effect on HDL concentrations was also apparent in the principal HDL protein component, apolipoprotein AI (-29% at 24 months, p<0.001). However, there was no significant effect of tibolone on low-density or very-low-density lipoprotein cholesterol (LDL-C and VLDL-C, respectively). By contrast, the greatest reduction in cholesterol with E2 /NETA was in LDL-C (-22% at 24 months, p=0.008). E2 /NETA reduced HDL-C to a lesser extent than tibolone (-12% at 24 months, p<0.001). Effects on HDL apolipoproteins were similarly diminished relative to tibolone. E2 /NETA had no effect on VLDL-C or on the protein component of LDL, apolipoprotein B.Tibolone reduces serum HDL. E2 /NETA reduces LDL cholesterol but not apolipoprotein B, suggesting decreased cholesterol loading of LDL. Any impact these changes may have on CVD risk needs further investigation.

Click here to read the full article @ Clinical endocrinology